# Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT05522985** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 122 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Chemotherapy

## Interventions

- **DRUG:** Triprilimab combined with TP

## Key facts

- **NCT ID:** NCT05522985
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-07
- **Primary completion:** 2025-11-07
- **Final completion:** 2027-11-07
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522985, "Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05522985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*